Cannabis Industry Challenges: Rescheduling and Banking Issues Explored

There’s a tension at the heart of the American cannabis industry that no earnings report can fully capture. It’s the quiet, persistent hum of legal uncertainty. I hear it in conversations with bankers on Maiden Lane, in the careful phrasing of corporate counsel, and in the strategic memos from venture capital firms dipping a toe into this green frontier. The recent buzz around potential federal rescheduling of cannabis from Schedule I to Schedule III has, understandably, sparked a wave of optimism. But from where I sit in the canyons of the Financial District, the view is more measured. This isn’t a simple on-off switch for legitimacy. It’s a complex rewiring of a financial and legal system that has, for decades, treated the plant as a pariah.

The core issue, one that veteran attorneys like Agustin Rodriguez consistently highlight, is the glaring conflict between state and federal law. Thirty-eight states have legalized cannabis in some form, creating a multi-billion dollar ecosystem of cultivators, processors, retailers, and service providers. Yet at the federal level, cannabis remains illegal under the Controlled Substances Act. This dissonance creates a cascade of practical problems, with banking access being the most acute. Major financial institutions, wary of running afoul of federal money laundering statutes and regulatory scrutiny, have largely steered clear. This forces legitimate businesses into a shadow economy of all-cash operations, creating immense security risks, audit nightmares, and barriers to basic financial services like lines of credit or business loans. A move to Schedule III would not eliminate this conflict, but it would fundamentally alter its character, potentially opening the door for more traditional banking relationships under revised guidance from the Financial Crimes Enforcement Network (FinCEN).

Rescheduling, however, is a double-edged sword. It brings certain issues into sharper focus while complicating others. On one hand, removing cannabis from the Schedule I category—reserved for drugs with “no currently accepted medical use”—would validate state medical programs and likely ease restrictions on research. It could also alleviate the crushing burden of Internal Revenue Code Section 280E, which currently prohibits cannabis businesses from deducting ordinary business expenses, a tax penalty that cripples profitability. The Congressional Research Service notes that rescheduling could have “significant implications” for federal tax policy toward these businesses. But for lawyers advising clients, new complexities emerge. How would rescheduling impact existing contract enforcement in state courts? Would it change the calculus for institutional investors or real estate investment trusts (REITs) considering cannabis assets? The regulatory uncertainty doesn’t vanish; it merely shifts to a new set of agencies, like the FDA, which would likely gain oversight authority over medical cannabis products.

The most precarious legal terrain may lie in the realm of insolvency. Today, a cannabis business facing financial distress has virtually no access to the federal bankruptcy courts, as those courts cannot administer an estate centered on an illegal federal activity. This leaves struggling companies and their creditors in a legal vacuum, relying on costly and inconsistent state-level receiverships or assignments for the benefit of creditors. Rescheduling to Schedule III could change this, theoretically allowing cannabis businesses to seek Chapter 11 protection. But as Rodriguez and other specialists point out, the path wouldn’t be automatic. Judges would still have to navigate a patchwork of state regulations, and the involvement of federal trustees in a still-federally-regulated industry presents uncharted procedural hurdles. For lenders and investors, this lack of a predictable insolvency framework is a major deterrent to capital deployment. It turns every loan or equity check into a higher-risk proposition.

So, what’s the pragmatic path forward for stakeholders? The advice I’m hearing from seasoned practitioners is to prepare for evolution, not revolution. Due diligence has always been king in finance, but here it requires an almost forensic level of detail. Attorneys are advising clients to build compliance-centric operations from the ground up, documenting every step to create an “audit trail” that could satisfy a future regulator or financier. They’re structuring investments and loans with layered security, often tying them to real estate or intellectual property rather than the cannabis inventory itself. And there’s a growing emphasis on state-level solutions, such as pushing for clearer commercial laws and creditor remedies within legalized states to build a parallel system of predictability.

The narrative that federal rescheduling will instantly normalize the cannabis industry is a seductive but simplistic one. The reality is more gradual, more nuanced. It will involve a protracted period of regulatory interpretation, legal testing, and financial adaptation. The challenge for attorneys—and for the bankers and investors who rely on their counsel—is to navigate this transition with eyes wide open. The goal isn’t just to survive the current legal limbo, but to build enterprises that are resilient enough to thrive in whatever hybrid system emerges. The market potential is undeniable, but as with any high-growth, high-volatility sector, the winners will be those who best understand the rules of the game, even as the rulebook is being rewritten.

• Legal uncertainty persists in the cannabis industry
• Conflict between state and federal law remains a major issue
• Rescheduling may open banking avenues but complicates other areas
• Insolvency options are currently limited for cannabis businesses
• Compliance-centric operations are becoming crucial for businesses
• The transition to normalization will be gradual